Z Gastroenterol 2025; 63(08): e425 DOI: 10.1055/s-0045-1810734
Abstracts | DGVS/DGAV
Kurzvorträge
Molekulare Therapie bei CED Donnerstag, 18. September 2025, 11:15 – 12:51, MZF 1
Long-term efficacy and safety of intravenous (IV) Tulisokibart in patients with crohn’s
disease (CD): Results from the open-label extension period of the phase 2 APOLLO-CD
study
Authors
M Sossdorf
1
MSD Sharp & Dohme GmbH, Munich, Deutschland
C A Siegel
2
Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology
and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, Vereinigte Staaten
R W Leong
3
Concord Hospital and Macquarie University Hospital, Sydney, Australien
J K Anderson
4
Merck & Co., Inc., Rahway, Vereinigte Staaten
M Yen
4
Merck & Co., Inc., Rahway, Vereinigte Staaten
B Dong
4
Merck & Co., Inc., Rahway, Vereinigte Staaten
B E Sands
5
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount
Sinai, New York, Vereinigte Staaten
S Danese
6
Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific
Institute, Vita-Salute San Raffaele University, Milan, Italien
B G Feagan
7
Departments of Medicine, Epidemiology, and Biostatistics, Western University, London,
Kanada
